News
Entertainment
Science & Technology
Life
Culture & Art
Hobbies
News
Entertainment
Science & Technology
Culture & Art
Hobbies
Xeltis appoints Shawn Gage VP US – Ysios Capital
Brings extensive experience in design, development, and implementation of US medtech clinical trial strategy for hemodialysis and vascular access Follows expansion of Xeltis’ clinical presence in the US after recent IDE approval for aXessTM US pivotal trial EINDHOVEN, Netherlands, July 23, 2024 /PRNewswire/ -- Xeltis, a leading developer of transformative implants that enable the natural creation of living and
Gloria Gonzalez receives the Rosalind Franklin Society Special Award in Science – Ysios Capital
Recognition of her pioneering gene therapy research Coordinated the first ever gene therapy clinical trial utilizing AAVs as a vector for the treatment of an inherited liver metabolic disease for acute intermittent porphyria Her work on AAVs has been instrumental in creating Vivet’s research platform and advancing development of Vivet’s lead gene therapy for Wilson’s
Leriglitazone halts disease progression – Ysios Capital
In a French early-access program study, 10 of 13 patients were clinically and radiologically stable Mataró, Barcelona, Spain, 11 June, 2024 - Minoryx Therapeutics (“Minoryx”), a late-stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders, today announce that results from a compassionate use study of leriglitazone for treatment of
Xeltis IDE approval from FDA aXess – Ysios Capital
aXess is a restorative arteriovenous dialysis conduit which allows vascular access for hemodialysis through the creation of a new, permanent, living vessel EINDHOVEN, The Netherlands, 13 June 2024 - Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, announces that it has gained approval from the US
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights – Ysios Capital
Enrolling Patients in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions; Granted SPA Agreement by FDA Data Expected Mid-2024 from Ongoing Phase 1 Trial in Bladder Cancer (Non-Muscle Invasive Bladder Cancer and Muscle Invasive Bladder Cancer) Strong Cash Position into Second Half of 2026 BOSTON--(BUSINESS WIRE)--Mar. 27, 2024-- Aura Biosciences, Inc. (NASDAQ: AURA),
Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies – Ysios Capital
Proceeds to Support Advancement of Engrail’s Pipeline for Neuropsychiatric and Neurodevelopmental Disorder SAN DIEGO – March 19, 2024 – Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company focused on the development of transformational therapies to improve the lives of patients, today announced the close of an oversubscribed $157 million Series B financing round. The
Ysios joins Neurona 120MUSD financing – Ysios Capital
The financing, co-led by Viking Global Investors and Cormorant Asset Management with participation from The Column Group along with additional new and existing investors, follows promising early clinical data from NRTX-1001 epilepsy program San Francisco, CA, February 8, 2024 – Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders,
Lava Therapeutics collaboration with Merck – Ysios Capital
Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC Enrollment will continue in the monotherapy and IL-2 combination arms of the study UTRECHT, The Netherlands and PHILADELPHIA, Jan. 25, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), today announced that it has entered into a clinical
Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation – Ysios Capital
Synendos Therapeutics transitions to a clinical-stage biotech company developing innovative Endocannabinoid System (ECS) treatments for neuropsychiatric, neuroinflammatory and other Central Nervous System (CNS) disorders Clinical Trial will investigate the safety, tolerability and pharmacokinetics of Synendos’ first-in-class ECS modulator BASEL, Switzerland – 18 January 2024 – Synendos Therapeutics AG (Synendos), a world leader in innovative Endocannabinoid System
Am-Pharma initiates Phase 2 trial of Ilofotase Alfa for Cardiac Surgery-Associated Renal Damage – Ysios Capital
Trial will evaluate ilofotase alfa as a treatment to prevent renal damage in at-risk patients following open heart surgery Ilofotase alfa’s clinical record of renal protective effects supports therapeutic potential in underserved and high-need indication Utrecht, The Netherlands, January 16, 2024 – AM-Pharma B.V. today announced that the first patients have been treated in a Phase 2 clinical
– Ysios Capital
Beijing, China and Barcelona, Spain, December 18th, 2023 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotech company focusing on the discovery and development of novel antibody therapeutics, today announces an antibody evaluation, option and license agreement with Ona Therapeutics (“Ona”), a Spanish biotech company specialized in unravelling novel biology to design
Outstanding 12-month first-in-human data from Xeltis’ aXess – Ysios Capital
aXess demonstrated exceptional patency rates and no infections to date EINDHOVEN, The Netherlands – 17 November 2023, Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, announces outstanding 12-month data from its first-in-human (FIH) aXess vascular conduit trial (NCT04898153). The data was presented yesterday by Prof. Dr.
Minoryx announces enrollment of first patients in US Phase 3 clinical trial, CALYX – Ysios Capital
As part of CALYX, Minoryx is conducting an extensive pre-screening MRI-based campaign aimed at identifying eligible adult X-ALD patients with cerebral Adrenoleukodystrophy (cALD) Mataró, Barcelona, Spain, November 16, 2023 - Minoryx Therapeutics, a registration stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders, today announces the first patients